| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1015: Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments |
|
Medicine details |
|
| Medicine name | teclistamab (Tecvayli®) |
| Formulation | Subcutaneous injection |
| Reference number | 5151 |
| Indication | Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 04/10/2022 |
| NICE guidance | TA1015: Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments |